IDEXX Laboratories Inc (IDXX)
NASDAQ · Healthcare · Diagnostics & Research
IDEXX Laboratories Inc is a Healthcare company with a market capitalization of $43.50B and a trailing P/E ratio of 40.6.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | $3.47 | $3.41 | +1.8% |
| Q4 2025 | February 2, 2026 | $3.08 | $2.94 | +4.8% |
| Q3 2025 | November 3, 2025 | $3.40 | $3.15 | +7.9% |
| Q2 2025 | August 4, 2025 | $3.63 | $3.30 | +10.0% |
| Q1 2025 | May 1, 2025 | $2.96 | $2.85 | +3.9% |
| Q4 2024 | February 3, 2025 | $2.62 | $2.40 | +9.2% |
Other Diagnostics & Research Stocks
Frequently Asked Questions
What is IDEXX Laboratories Inc's market cap?
As of June 29, 2026, IDEXX Laboratories Inc (IDXX) has a market capitalization of $43.50B.
What is IDEXX Laboratories Inc's P/E ratio?
IDEXX Laboratories Inc trades at a trailing price-to-earnings (P/E) ratio of 40.6. Its forward P/E is 37.5.
Does IDEXX Laboratories Inc pay a dividend?
IDEXX Laboratories Inc does not currently pay a dividend.
What sector is IDXX in?
IDEXX Laboratories Inc is in the Healthcare sector, specifically the Diagnostics & Research industry.
What was IDEXX Laboratories Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), IDEXX Laboratories Inc reported revenue of $4.30B and net income of $1.06B.
Ask your own questions about IDXX
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.